Investigating the effect of azithromycin on gullet function in patients with long-term respiratory disease

Not Applicable

• Conditions: Ashtma, cough, lung fibrosis, COPD; Respiratory

• Registration Number: ISRCTN16059833
• Lead Sponsor: Hull University Teaching Hospitals NHS Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-12-16
• Last Update Posted: 8 July 2024
• Study Completion: 2024-08-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. Males and females aged =18 years
2. Have a diagnosis of chronic respiratory disease (COPD, asthma, interstitial lung disease, chronic cough, cystic fibrosis, and/or bronchiectasis) confirmed by a respiratory consultant
3. Exhibit symptoms consistent with airway reflux, demonstrated by a score =14 on the Hull Airways Reflux Questionnaire
4. Are being initiated on azithromycin as part of routine clinical care, as judged by their usual respiratory clinician. This will include all common treatment regimes, 250mg once daily, 250mg three times per week, and 500mg three time per week.
5. Are willing and able to consent to all study procedures

Exclusion Criteria

1. Previous treatment with long-term macrolides in the past 3 months
2. Unable to be investigated with HROM due to contraindications such as anatomical abnormalities or diseases of the oesophagus or unwilling/ unable to be investigated with HROM based on the clinical judgement of the investigators due to the severity of lung disease
3. Have another cardiorespiratory cause for their symptoms (such as heart failure or lung cancer)
4. Women of childbearing potential not using effective means of contraception
5. Are unable or unwilling to consent to or complete the study procedures

Study & Design

• Study Type: Interventional
• Study Design: Not specified